Trial Profile
FINITE CHB - First Investigation in Stopping Tenofovir Disoproxil Fumarate (TDF) Treatment After Long Term Virologic Suppression in HBeAg-negative Chronic Hepatitis B.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms FINITE CHB
- Sponsors Gilead Sciences
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
- 20 Jul 2017 Primary endpoint (Proportion of participants with HBsAg loss at Week 144 in both study arms) has been met,as per the results published in the Journal of Hepatology.
- 20 Jul 2017 Results published in the Journal of Hepatology